Literature DB >> 22802474

Persistent coagulopathy during Escherichia coli sepsis in a previously healthy infant revealed undiagnosed tyrosinaemia type 1.

H Georgouli1, K H Schulpis, H Michelakaki, M Kaltsa, T Sdogou, L Kossiva.   

Abstract

Hereditary tyrosinaemia type 1 (HT1) is caused by an enzymatic defect in tyrosine metabolism. It is an autosomal recessive disorder and affects both sexes equally. In young infants HT1 can present as severe liver involvement and in older infants as liver failure and renal tubular dysfunction together with growth failure and rickets. The authors report the case of a 5-month-old, previously healthy, male infant who presented with Escherichia coli sepsis and severe coagulopathy due to liver dysfunction. Despite the early diagnosis of HT1 and treatment with 2-(2-nitro-4-trifluoromethylbenzoyl)-1, 3-cyclohexanedione (NTBC), the patient died from severe coagulopathy and multi-organ failure.

Entities:  

Mesh:

Year:  2010        PMID: 22802474      PMCID: PMC3029516          DOI: 10.1136/bcr.07.2010.3150

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  6 in total

1.  Mutation screening for tyrosinaemia type I.

Authors:  S K Heath; R G F Gray; P McKiernan; K M Au; E Walker; A Green
Journal:  J Inherit Metab Dis       Date:  2002-10       Impact factor: 4.982

2.  Tyrosinemia type 1 should be suspected in infants with severe coagulopathy even in the absence of other signs of liver failure.

Authors:  J M Croffie; S K Gupta; S K Chong; J F Fitzgerald
Journal:  Pediatrics       Date:  1999-03       Impact factor: 7.124

3.  A single mutation of the fumarylacetoacetate hydrolase gene in French Canadians with hereditary tyrosinemia type I.

Authors:  M Grompe; M St-Louis; S I Demers; M al-Dhalimy; B Leclerc; R M Tanguay
Journal:  N Engl J Med       Date:  1994-08-11       Impact factor: 91.245

4.  On the enzymic defects in hereditary tyrosinemia.

Authors:  B Lindblad; S Lindstedt; G Steen
Journal:  Proc Natl Acad Sci U S A       Date:  1977-10       Impact factor: 11.205

5.  Serum levels of oncofetal markers CA 125, CA 19-9, and alpha-fetoprotein in children with hereditary tyrosinemia type I.

Authors:  S Pitkänen; M K Salo; P Kuusela; C Holmberg; O Simell; M Heikinheimo
Journal:  Pediatr Res       Date:  1994-02       Impact factor: 3.756

6.  Cloning and expression of the cDNA encoding human fumarylacetoacetate hydrolase, the enzyme deficient in hereditary tyrosinemia: assignment of the gene to chromosome 15.

Authors:  D Phaneuf; Y Labelle; D Bérubé; K Arden; W Cavenee; R Gagné; R M Tanguay
Journal:  Am J Hum Genet       Date:  1991-03       Impact factor: 11.025

  6 in total
  4 in total

1.  Geographical and Ethnic Distribution of Mutations of the Fumarylacetoacetate Hydrolase Gene in Hereditary Tyrosinemia Type 1.

Authors:  Francesca Angileri; Anne Bergeron; Geneviève Morrow; Francine Lettre; George Gray; Tim Hutchin; Sarah Ball; Robert M Tanguay
Journal:  JIMD Rep       Date:  2015-02-15

2.  Tyrosinemia type 1: a rare and forgotten cause of reversible hypertrophic cardiomyopathy in infancy.

Authors:  Sarar Mohamed; Mohammed A Kambal; Nasir A Al Jurayyan; Abdulrahman Al-Nemri; Amir Babiker; Rana Hasanato; Abdullah S Al-Jarallah
Journal:  BMC Res Notes       Date:  2013-09-09

3.  Mutational spectrum of Mexican patients with tyrosinemia type 1: In silico modeling and predicted pathogenic effect of a novel missense FAH variant.

Authors:  Isabel Ibarra-González; Cynthia Fernández-Lainez; Miguel Angel Alcántara-Ortigoza; Ariadna González-Del Angel; Liliana Fernández-Henández; Sara Guillén-López; Leticia Belmont-Martínez; Lizbeth López-Mejía; Gustavo Varela-Fascinetto; Marcela Vela-Amieva
Journal:  Mol Genet Genomic Med       Date:  2019-09-30       Impact factor: 2.183

4.  Persistent coagulopathy during Streptococcus pneumoniae sepsis and left foot abscess in a previously healthy infant revealed tyrosinemia.

Authors:  Bing Liu; Lingyun Guo; Xue Ning; Gang Liu
Journal:  Pediatr Investig       Date:  2021-10-24
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.